CEVR analyzes the value of strategies to improve health and health care.

About Us

News

The ‘Pharm-To-Table’ Movement For Prescription Drugs: Promising Or Performative?
A growing number of drugmakers are rolling out “pharm-to-table” initiatives to sell drugs directly to patients at lower costs. However, the extent to ...
Read more December 5, 2025
How Well Has Cost-Effectiveness Predicted Drug Market Success? Evidence of Omitted Value
Summary: Pharmaceutical markets differ from competitive markets, often producing prices that do not fully reflect societal value. Traditional cost-eff...
Read more December 4, 2025
Call for Papers: 2025 Tufts-CEVR Papers of the Year
The Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center is thrilled to announce two award opportunities recognizing o...
Read more December 3, 2025
View All News Items

Events

CEVR Participation at ISPOR EU 2025
Learn more
November 10–12, 2025
CEVR Health Policy Seminar with Boshen Jiao, PhD, MPH
Learn more
2:30–3:30 on November 5, 2025
CEVR Health Policy Seminar with Carl Asche, PhD, MSc
Learn more
2:00–3:00 on September 30, 2025
View All Events

Recent Publications

Health Affairs Forefront
The ‘Pharm-To-Table’ Movement For Prescription Drugs: Promising Or Performative?
View publication
December 5, 2025
Medical Decision Making
When Do Published Cost-Effectiveness Analyses Include Societal Costs? An Empirical Analysis, 2013–2023
View publication
December 1, 2025
Health Affairs Scholar
The Unintended Consequences of the Inflation Reduction Act on Biosimilar Market Incentives and Medicare Savings
View publication
November 19, 2025
The Journal of Pediatrics
Rapid Genome Sequencing Compared with a Gene Panel in Critically Ill Infants with a Suspected Genetic Disorder: An Economic Evaluation
View publication
October 31, 2025
JAMA
Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene Therapies
View publication
September 29, 2025
Journal of Pain and Symptom Management
Bereavement Experiences Among Parents of Children With Spinal Muscular Atrophy Type 1
View publication
September 22, 2025
Value In Health
Cost-Effectiveness of the 15 Drugs Selected for Initial Price Applicability Year 2027 by Centers for Medicare and Medicaid Services Drug Price Negotiation Program
View publication
September 10, 2025
Value in Health
Mental Health, Quality of Life, and Work Functioning of Parents of Children Who Have Died of Spinal Muscular Atrophy
View publication
September 10, 2025
View All Publications

The CEVR Team

Our team of experienced, dedicated researchers is led by health economists Peter Neumann and Josh Cohen. Together we produce cutting-edge health care cost-effectiveness research.

Meet the CEVR Team

Our Databases

Our comprehensive databases provide the information individuals and organizations need to analyze the benefits, risks, and costs of strategies to improve health and health care.

CEA Registry

The CEA Registry is a comprehensive database of 9,080 cost-utility analyses on a wide variety of diseases and treatments.

View Registry

Global Health CEA Registry

The GH CEA Registry is the first comprehensive database to compile articles utilizing the “cost-per-DALY averted” metric to measure the efficacy of health interventions.

View Registry

SPEC Database

The Specialty Drug Evidence and Coverage (SPEC) Database is a new data resource developed with the goal of providing an empirical basis to commercial payer specialty drug coverage.

View Database
Learn About Our Databases